Trial · NCT02497157
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
NCT02497157, Phase 2, Completed, Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer. Trials, record NCT02497157. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02497157
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
- NCT number
- NCT02497157
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Oxaliplatin (L-OHP), Irinotecan hydrochloride hydrate (CPT-11), Continuous intravenous infusion of fluorouracil (CIV 5-FU), Levofolinate calcium (l-LV), Bevacizumab (Bmab)
- First posted
- 2015-07-14
- Last updated
- 2020-06-17
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1) | Up to 18 months | RR will be calculated as the ratio of the number of eligible patients who experienced a confirmed Complete response(CR) or Partial response(PR) by RECIST v1.1. |
| Secondary | Time to treatment failure (TTF) | Up to 18 months | TTF is defined as the time from date of starting treatment until date of treatment discontinuation, the first documented progression or death from any cause, whichever comes first. |
| Secondary | Progression-free survival (PFS) | Up to 3 years | PFS is defined as the time from date of starting treatment until date of the first documented progression or death from any cause, whichever comes first. |
| Secondary | Overall survival (OS) | Up to 3 years | OS is defined as the time from date of starting treatment until date of death from any cause. |
| Secondary | R0 resection rate | Up to 18 months | R0 resection rate will be calculated as the ratio of the number of eligible patients who experienced a complete (R0) resection. |
| Secondary | Relative dose intensity (RDI) | Up to 18 months | RDI will be calculated as the ratio of actual delivered dose intensity in comparison with planned dose intensity. Dose intensity (DI) is defined as the amount of drug delivered per unit time, expressed in mg/m2/week. |
| Secondary | Incidence of adverse events | Up to 3 years | |
| Other | Early tumor shrinkage (ETS) rates in 8 weeks after starting the treatment, evaluated by RECIST v1.1 | Baseline (week 0), week 8 | ETS will be calculated as the ratio of the number of eligible patients who experienced a 20% or more tumor shrinkage at week 8 compared with baseline. |
| Other | Deepness of response (DoR) | Up to 3 years | DoR will be calculated as the median of the maximum tumor shrinkage rates. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02497157
GET https://conductscience.org/api/trials/v1/NCT02497157/registered